H.C. Wainwright lowered the firm’s price target on Akebia (AKBA) to $6 from $8 and keeps a Buy rating on the shares. The firm cites the announcement of the company not pursuing initiation of the Phase 3 VALOR trial or associated broad chronic kidney disease non-dialysis labeling for Vafeso for the target drop.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics Halts VALOR Trial for Vadadustat
- Akebia says not in alignment with FDA on path forward for VALOR clinical trial
- Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Implications for Investors
- Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications
- Akebia’s Vadadustat Study: A Potential Game-Changer in Anemia Treatment for CKD